Sickle Cell Disease Treatment Gets Panel Nod Despite Efficacy Concerns
US FDA's Oncologic Drugs Advisory Committee votes 10-3 in favor of approving Emmaus' L- glutamine, touting its strong safety profile and the unmet clinical need in spite of agency's questions about efficacy results.